<DOC>
	<DOCNO>NCT01882387</DOCNO>
	<brief_summary>The purpose study evaluate efficacy TXA127 reduce incidence ( Grade II-IV ) acute Graft-vs.-Host Disease ( aGVHD ) adult subject undergo allogeneic peripheral blood stem cell transplantation ( PBSCT ) . The study also evaluate effect TXA127 incidence , severity duration mucositis ; neutrophil engraftment platelet recovery ; platelet transfusion requirement ; immune reconstitution ; duration corticosteroid use . TXA127 show well tolerated patient appear induce rapid production neutrophil platelet bloodstream , well increase immune system component . TXA127 also show reduce severity chemotherapy-induced mucositis .</brief_summary>
	<brief_title>Efficacy Study TXA127 Reduce Graft-vs-Host Disease Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation</brief_title>
	<detailed_description>Allogeneic hematopoietic stem cell transplantation ( HSCT ) increasingly used effective treatment malignant disease . The three common source stem cell use HSCT bone marrow ( BM ) , umbilical cord blood ( UCB ) , peripheral blood stem cell ( PBSC ) . In retrospective review 1,525 adult acute leukemia receive allogeneic transplant 2002 2006 , UCB account 10.8 % , PBSC 58.2 % , BM 31 % population ( Eapen et al. , 2010 ) . PBSC source hematopoietic stem cell transplantation advantage bone marrow term donation ease comfort cord blood term adequate cell dose . However , PBSC transplantation associate increased incidence graft-versus-host disease ( GVHD ) . Based current literature acute GVHD ( aGVHD ) report 48-80 % PBSCT recipient ( Eapen et al. , 2010 , Ferrara et al. , 2009 ) . Additionally , myeloablative conditioning regimen use transplant often result mucositis debilitate patient . TXA127 pharmaceutically-formulated angiotensin 1-7 , non-hypertensive derivative angiotensin II . TXA127 multilineage effect hematopoietic progenitor vitro vivo . The hematopoietic property demonstrate preclinical clinical study support investigation TXA127 reduce incidence aGVHD mucositis patient population .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Angiotensin I ( 1-7 )</mesh_term>
	<criteria>Provided write informed consent . â‰¥18 year age . Meet institutional standard criterion PBSC transplantation Myeloablative conditioning regimen Histologically confirm diagnosis hematologic malignancy . Life expectancy &gt; 4 month . Female subject capable reproduction ( define subject start menses ) must agree follow : 1 ) Use effective oral IM contraceptive method course study 2 month follow last administration Investigational Product ; 2 ) must negative pregnancy test result within 7 day prior first Investigational Product dose . Uncontrolled infection time transplant . Pregnant breastfeeding . Known seropositive HIV HTLV1 . Active CNS disease time study enrollment . Treatment investigational agent within 30 day anticipate administration first dose Investigational Product . Current alcohol use , illicit drug use condition ( e.g. , psychiatric disorder ) , opinion Investigator , may interfere subject 's ability comply study requirement visit schedule . Any comorbid condition , view Principal Investigators , render subject high risk treatment complication regimenrelated morbidity/mortality . Prophylactic treatment palifermin mucositis . Subjects know sensitivity Investigational Product component .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Allogeneic Peripheral Blood Stem Cell Transplantation</keyword>
	<keyword>Graft-vs-Host Disease</keyword>
	<keyword>Neutrophil Engraftment</keyword>
	<keyword>Platelet Engraftment</keyword>
	<keyword>Immune Reconstitution</keyword>
	<keyword>Mucositis</keyword>
</DOC>